简介：ObjectivesToinvestigatetheeffectsoftestosteroneenanthate(TE)onserumlipidsandlipoproteinsmetabolismandtheexpressionofandrogenreceptor(AR),estrogenreceptorbeta(ER-β)andplateletderivedgrowthfactorbeta(PDGFR-β)inaorticvascularsmoothmuscletissues(VSMTs).MethodsFortyagedmaleratswererandomlydividedinto4groups,groupA(placebogroup),groupB(2.5mg/kgintramuscularinjectionofTEonceaweek),groupC(5.0mg/kgintramuscularinjectionofTEonceaweek),groupD(10.0mg,/kgintramuscularinjectionofTEonceaweek).Allanimalswerefedfreelyduring16-weektreatmentperiods.TheexpressionofAR,ER-βandPDGFR-βwerestudiedbyWesternbolt.ResultsAverageserumLDL-CwasloweringroupDthanthatingroupA(p＜0.01).Comparedwiththeothergroups,averageserumTCwasalsoloweringroupD(p＜0.05).ARexpressioninaorticvascularsmoothmuscletissuescouldberegulatedbyTE:99.50±21.74,125.38±28.68and101.98±15.42forTEconcentrationsat2.5mg/kg,5.0mg/kgand10.0mg/kg,respectively,theexpressionofER-βcouldberegulatedbyTE:92.34±18.68,47.72±18.12,82.13±23.50,andtheexpressionofPDGFR-βcouldberegulatedaswellbyTE:219.70±45.59,50.16±9.72,125.36±15.74(DataforAR,ER-βandPDGFR-βproteinbandintensitywereexpressedwithx±s,withcontrolgrouptakenas100).ConclusionsThisstudyindicatesthatandrogenshavesignificanteffectsonserumlipidsandlipoproteinmetabolism.Testosteroneenanthateat5.0mg/kgcanstimulatetheexpressionofAR,butinhibitetheexpressionofPDGFR.Testosteroneenanthateattheconcentrationsof5.0mg/kgand10.0mg/kgcaninhibitetheexpressionofER-β.

简介：目的调查卒中患者便秘的发生情况及其影响因素,并建立便秘发生的函数预测模型.方法对2003年11月至2004年3月收治的64例卒中患者进行便秘的前瞻性调查,并对随访资料进行生存分析;建立便秘发生的函数预测模型及便秘是否发生的判别函数,并对资料进行回代检验.结果卒中患者便秘的发生率为60.93%(39/64),影响卒中患者发生便秘的主要因素是年龄和发病1周时总的生活能力状态的评分.卒中患者便秘发生的模型为h(t,X)=h0(t)exp(0.84X1+0.03X2);便秘发生判别函数为Y(1)=-27.67+4.84X1+0.30X2.结论卒中患者发病后10d内便秘的发生率较高,年龄较大且生活能力状态较低的卒中患者比较容易发生便秘.